

IMAGE IN CARDIOLOGY

Percutaneous implantation of a Sapiens 3 valve-in-valve in mitral position: A case report involving correction of prosthetic mitral valve regurgitation



Implantação percutânea de valve-in-valve Sapiens 3 em posição mitral: um caso clínico de correção de regurgitação de prótese valvular mitral

Miguel Martins de Carvalho ^{a,b,*}, Ricardo Alves Pinto ^a, Tânia Proença ^a, Mariana Paiva ^a, Carla Sousa ^{a,b}, João Carlos Silva ^a, Filipe Macedo ^{a,b}

^a Department of Cardiology, Centro Hospitalar Universitário de São João, Porto, Portugal

^b Cardiovascular R&D Center, Faculty of Medicine of the University of Porto São João, Porto, Portugal

Received 1 November 2022; accepted 12 December 2022

Available online 4 April 2023

Currently, the treatment for most valve diseases requiring intervention is surgical; and there are unmet clinical needs in patients who are inoperable due to high surgical risk. This is the case of up to 49% of patients requiring mitral valve intervention.^{1,2}

We describe the case of an 85-year-old man who underwent mitral replacement surgery with a biological prosthesis (Carpentier-Edwards SAV 29) in 2011. In October 2020, he developed signs of heart failure. An echocardiogram was performed, revealing severe mitral bioprosthetic regurgitation, due to cusp prolapse (Video 1); preserved biventricular systolic function and major pulmonary hypertension. Due to his advanced age, frailty and having undergone previous cardiac surgery, the risk of new surgery was deemed

too high. The decision was taken to perform a percutaneous mitral valve-in-valve implantation of a Sapiens 3 Ultra-29. The valve was inserted via transseptal puncture, with transesophageal echocardiogram and fluoroscopy guidance (Video 1). During valve deployment, rapid ventricular pacing was applied. After valve implantation, a small peri-prosthesis leak was observed. There was no interference with the adjacent cardiac structures (Video 2); the mean transvalvular gradient was 5 mmHg. The patient improved and was discharged five days later.

Biological valves are being used increasingly,^{3,4} however, their longevity is shorter and the consequently the number of patients with degeneration of bioprosthetic valves will increase. The balloon-expandable Sapiens 3 valve is designed to be deployed in a rigid structure, so that the radial force of the balloon expanding valve provides support.² This procedure should be considered in high surgical risk patients (Figure 1).

* Corresponding author.

E-mail address: jmiguelmartinscarvalho@gmail.com

(M. Martins de Carvalho).




Figure 1 (A and B) Severe mitral prosthesis regurgitation due to cusp prolapse, jets directed posterior-laterally and to the left atrial appendage; implantation of an Edwards Sapiens 3 Ultra-29 valve, with transesophageal echocardiography (C) and fluoroscopy (D) guidance; (E) final result: no signs of interference in the adjacent cardiac structures; a small lateral peri-prosthesis leak was observed.

Conflicts of interest

The authors have no conflicts of interest to declare.

Appendix A. Supplementary data

Supplementary material associated with this article can be found in the online version at doi:10.1016/j.repc.2022.12.015.

2. Puri R, Abdul-Jawad O, del Trigo M, et al. Transcatheter mitral valve implantation for inoperable severely calcified native mitral valve disease: a systematic review. *Catheter Cardiovasc Interv*. 2016;87:540–8.
3. Yoon SH, Whisenant B, Bleiziffer S, et al. Outcomes of transcatheter mitral valve replacement for degenerated bioprostheses, failed annuloplasty rings, and mitral annular calcification. *Eur Heart J*. 2019;40:441–51.
4. Goldstone AB, Chiu P, Baiocchi M, et al. Mechanical or biologic prostheses for aortic-valve and mitral-valve replacement. *N Engl J Med*. 2017;377:1847–57.

References

1. Mirabel M, Iung B, Baron G, et al. What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? *Eur Heart J*. 2007;28:1358–65.